{
    "2020-03-30": [
        [
            {
                "time": "2023-10-17",
                "original_text": "Lilly's TaltzÂ® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis",
                "features": {
                    "keywords": [
                        "Taltz",
                        "ixekizumab",
                        "FDA Approval",
                        "Pediatric Patients",
                        "Plaque Psoriasis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}